Invivyd Q1 net product revenue $13.7M (+22% YoY); net loss $41.4M; VYD2311 data delayed to Q3 2026

Invivyd, Inc.

Q1 2026 PEMGARDA net product revenue $13.7M, up 22% YoY vs $11.3M.
Net loss $41.4M ($0.13/sh) vs $16.3M ($0.14/sh) in Q1 2025; R&D expense rose to $30.7M.
Cash $184.2M at Mar 31; raised ~$20M via ATM in Apr 2026, extending runway through VYD2311 launch.
DECLARATION trial upsized by ~500 subjects; top-line data now expected in Q3 2026 (shift from mid-year).
IDMC reduced VYD2311 post-dose monitoring from 2 hours to 30 min; in vitro neutralization vs BA.3.2.2 confirmed.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Invivyd, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 14, 2026, Invivyd, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026, and recent business highlights.

View on SEC.gov

Browse all earnings releases →

Invivyd, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-222762

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.